HHE Pathology and diagnostics supplement 2018 - Page 13

References 1 Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Molec Med 2010;16(9):398–406. 2 Merker JD et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018:Jco2017768671. 3 Cristofanilli M et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351(8):781–91. 4 Cohen SJ et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(19):3213–21. 5 de Bono JS et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14(19):6302–9. 6 Zhang L et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012;18(20):5701–10. 7 Bidard FC et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014;15(4):406–14. 8 Baccelli I et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31(6):539–44. 9 Yang L et al. Optimization of an enrichmen t process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng 2009;102(2):521–34. 10 Lara O et al. Enrichment of rare cancer cells through depletion of normal cells using density and flow- through, immunomagnetic cell separation. Exp Hemetol 2004;32(10):891–904. 11 Alix-Panabieres C, Mader S, Pantel K. Epithelial-mesenchymal plasticity in circulating tumor cells. J Molec Med (Berlin, Germany) 2017;95(2):133–42. 12 Powell AA et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012;7(5):e33788. 13 Giordano A et al. Epithelial- mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 2012;11(11):2526–34. 14 Ramirez P et al. Oncological evaluation by positron-emission tomography, circulating tumor cells and alpha fetoprotein in patients with hepatocellular carcinoma on the waiting list for liver transplantation. Transplant Proc 2016;48(9):2962–5. 15 Bredemeier M et al. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget 2016;7(27):41677–90. 16 Autebert J et al. High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection. Lab Chip 2015;15(9):2090–101. 17 Karabacak NM et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc 2014;9(3):694–710. 18 Seal SH. Silicone flotation: a simple quantitative method for the isolation of free-floating cancer cells from the blood. Cancer 1959;12(3):590–5. 19 Desitter I et al. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res 2011;31(2):427– 41. 20 Farace F et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 2011;105(6):847–53. 21 Adams DL et al. The systematic study of circulating tumor cell isolation using lithographic microfilters. RSC Adv 2014;9:4334–42. 22 Adams DL et al. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch((R)) CTC test. Cytometry A 2015;87(2):137–44. 23 Xu L et al. Optimization and evaluation of a novel size based circulating tumor cell isolation system. PLoS One 2015;10(9):e0138032. 24 Lemaire CA et al. Fast and label-free isolation of circulating tumor cells from blood: From a research microfluidic platform to an automated fluidic instrument, VTX-1 Liquid Biopsy System. SLAS Technol 2018;23(1):16–29. 25 Hou HW et al. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep 2013;3:1259. 26 Balasubramanian P et al. Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream(R) system. PLoS One 2017;12(4):e0175414. 27 Ilie M et al. “Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PloS One 2014;9(10):e111597. 28 Vona G et al. Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000;156(1):57–63. 29 Harouaka RA et al. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin Chem 2014;60(2):323–33. 30 Sarioglu AF et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods 2015;12(7):685–91. 31 Krivacic RT et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A 2004;101(29):10501–4. 32 Somlo G et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat 2011;128(1):155–63. 33 Ntouroupi TG et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer 2008;99(5):789–95. 34 Pailler E et al. Method for semi-automated microscopy of filtration-enriched circulating tumor cells. BMC Cancer 2016;16:477. 35 Lustberg MB et al. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res 2014;16(2):R23. 36 Zhang L et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 2013;5(180):180ra48. 37 Heitzer E et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 2013;73(10):2965–75. 38 Abonnenc M et al. Programmable interactions of functionalized single bioparticles in a dielectrophoresis-based microarray chip. Anal Chem 2013;85(17):8219–24. 39 Fabbri F et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett 2013;335(1):225–31. 40 Mesquita B et al. Molecular analysis of single circulating tumour cells following long-term storage of clinical samples. Mol Oncol 2017;11(12):1687–97. 41 Paolillo C et al. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells. Clin Cancer Res 2017;23(20):6086–93. 42 Peeters DJ et al. Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer 2013;108(6):1358–67. 43 Esmaeilsabzali H et al. Detection and isolation of circulating tumor cells: principles and methods. Biotechnol Adv 2013;31(7):1063–84. 44 Riethdorf S, Wikman H, Pantel K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008;123(9):1991–2006. 45 Fehm T et al. De tection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009;11(4):R59. 46 Punnoose EA et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010;5(9):e12517. 47 Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8(5):329–40. 48 Chebouti I et al. ERCC1- expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post- therapeutic outcome of ovarian cancer. Oncotarget 2017;8(15):24303–13. 49 Soler A et al. EpCAM- Independent enrichment and detection of viable circulating tumor cells using the EPISPOT 13 HHE 2018 | hospitalhealthcare.com assay. Methods Mol Biol 2017;1634:263–76. 50 Cayrefourcq L et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 2015;75(5):892–901. 51 Deneve E et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem 2013;59(9):1384–92. 52 Kuske A et al. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Sci Rep 2016;6:39736. 53 Markou A et al. Multiplex gene expression profiling of in vivo isolated circulating tumor cells in high-risk prostate cancer patients. Clin Chem 2018;64(2):297–306. 54 Alix-Panabieres C. EPISPOT assay: detection of viable DTCs/ CTCs in solid tumor patients. Recent Results Cancer Res 2012;195:69–76. 55 Tulley S et al. Vita-Assay method of enrichment and identification of circulating cancer cells/circulating tumor cells (CTCs). Methods Mol Biol 2016;1406:107–19. 56 Friedlander TW et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer 2014;134(10):2284–93. 57 Lu J et al. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 2010;126(3):669–83. 58 Hodgkinson CL et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014;20(8):897–903. 59 Riethdorf S et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010;16(9):2634– 45. 60 Jaeger BAS et al. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial. PLoS One 2017;12(6):e0173593. 61 Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27(4):450–61. 62 Mazel M et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 2015;9(9):1773–82. 63 Paoletti C et al. Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. Cancer Res 2018;78(4):1110–22. 64 Sho S et al. Precision oncology using a limited number of cells: optimization of whole genome amplification products for sequencing applications. BMC Cancer 2017;17(1):457. 65 Denis JA, Lacorte JM. Detection of RAS mutations in circulating tumor cells: applications in colorectal cancer and prospects. Ann Biol Clin (Paris) 2017;75(6):607–18. 66 Obermayr E et al. Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. Oncotarget 2017;8(63):106415–28. 67 Podolak J et al. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget 2017;8(42):71447–55.